Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Value-Based Reimbursement For Antibiotics Gets Skeptical Reception

Executive Summary

Duke Margolis Center floats idea of market entry payments tied to insurance contracts, but insurers and even some sponsors raise concerns, highlighted by question of what constitutes value.

You may also be interested in...



US FDA Joins Chorus Of Concerns About Results Of GAIN Act

It's too early to say whether program is working, FDA tell Congress; agency has awarded 147 QIDP designations, but none of 12 approved antibacterals have new mechanism of action.

AMR Roundtable: The Push And Pull Of Antimicrobial Development Incentives (Part 1)

The Pink Sheet spoke with CEOs of antibiotic firm Zavante and antifungal specialist Amplyx as well as a BARDA official during a roundtable discussion at the recent BIO convention about what's needed to boost antimicrobial drug development, including "push" and "pull" incentives for drug makers.

‘Wildcard’ Patents: Why A REVAMP-ed Proposal Might Work In 2017

Before election day, the idea of a new transferrable exclusivity incentive seemed like an extreme long shot for enactment. But now advocates think it has a real chance – and a strategy to redraft the idea to answer Democratic critics and avoid a high CBO score.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS119507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel